ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes
Favour A. Akinjiyan,George Nassief,Jordan Phillipps,Tolulope Adeyelu,Andrew Elliott,Farah Abdulla,Alice Y. Zhou,George Souroullas,Kevin B. Kim,Ari Vanderwalde,Soo J. Park,George Ansstas
DOI: https://doi.org/10.1038/s41598-024-54136-3
IF: 4.6
2024-02-13
Scientific Reports
Abstract:ARID genes encode subunits of SWI/SNF chromatin remodeling complexes and are frequently mutated in human cancers. We investigated the correlation between ARID mutations, molecular features, and clinical outcomes in melanoma patients. Cutaneous melanoma samples (n = 1577) were analyzed by next-generation sequencing. Samples were stratified by pathogenic/likely pathogenic mutation in ARID genes ( ARID1A/2/1B/5B ). PD-L1 expression was assessed using IHC (SP142; positive (+): ≥ 1%). Tumor mutation burden (TMB)-high was defined as ≥ 10 mutations/Mb. Transcriptomic signatures predictive of response to immune checkpoint inhibitors—interferon gamma and T-cell inflamed score were calculated. Real-world overall survival (OS) information was obtained from insurance claims data, with Kaplan–Meier estimates calculated from time of tissue collection until last date of contact. Mann–Whitney U, Chi-square, and Fisher exact tests were applied where appropriate, with p values adjusted for multiple comparisons. ARID2 mutations were more prevalent in cutaneous melanoma compared to ARID1A (11.0%: n = 451 vs 2.8%: n = 113), with concurrent ARID1A / ARID2 mutation in 1.1% (n = 46) of samples. ARID mutations were associated with a high prevalence of RAS pathway mutations— NF1 ( ARID1A , 52.6%; ARID2 , 48.5%; ARID1A/2 , 63.6%; and ARID-WT, 13.3%; p < 0.0001) and KRAS ( ARID1A , 3.5%; ARID2 , 3.1%; ARID1A/2 , 6.5%; and ARID-WT, 1.0%; p = 0.018)), although BRAF mutations were less common in ARID-mutated cohorts ( ARID1A , 31.9%; ARID2 , 35.6%; ARID1A/2 , 26.1%; and ARID-WT, 50.4%; p < 0.0001). TMB-high was more common in ARID-mutated samples ( ARID1A , 80.9%; ARID2 , 89.9%; ARID1A/2 , 100%; and ARID-WT, 49.4%; p < 0.0001), while PD-L1 positivity was similar across subgroups ( ARID1A , 43.8%; ARID2 , 51.1%; ARID1A/2 , 52.5%; and ARID-WT, 44.9%; p = 0.109). Patients with ARID1A mutations had a higher prevalence of dMMR/MSI-H compared to those with ARID-WT (2.7% vs 0.2%, p = 0.030). Median IFN-γ and T-cell signatures were higher in ARID2 -mutated samples compared to ARID-WT (IFN-γ: − 0.15 vs − 0.21, p = 0.0066; T-cell: 23.5 vs − 18.5, p = 0.041). ARID2- mutated patients had improved survival compared to ARID-WT; (HR: 1.22 (95% CI 1.0–1.5), p = 0.022). No additional OS benefit was observed with anti-PD-1 therapy for ARID2 mutation compared to ARID -WT. Melanoma patients with ARID mutations exhibited higher prevalence of markers associated with ICI response, including TMB-H, and immune-related signatures. Our data also suggests improved survival outcome in patients with ARID2 mutations, irrespective of anti-PD1 therapy.
multidisciplinary sciences